GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Net Issuance of Debt

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Net Issuance of Debt : $3.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Telomir Pharmaceuticals's net issuance of debt for the three months ended in Mar. 2024 was $-0.10 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was $3.02 Mil.

Telomir Pharmaceuticals Net Issuance of Debt Historical Data

The historical data trend for Telomir Pharmaceuticals's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Net Issuance of Debt Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Net Issuance of Debt
- 0.46 3.12

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only - -0.09 2.14 1.07 -0.10

Telomir Pharmaceuticals Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telomir Pharmaceuticals Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Net Issuance of Debt
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024